


## KCL-286

Cat. No.:	HY-111573
CAS No.:	1952276-71-9
Molecular Formula:	C <sub>19</sub> H <sub>14</sub> N <sub>2</sub> O <sub>4</sub>
Molecular Weight:	334.33
Target:	RAR/RXR
Pathway:	Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



## BIOLOGICAL ACTIVITY

Description	Anticancer agent 168 is an orally active retinoic acid receptor (RAR/RXR) beta2 agonist with ameliorating effects on spinal cord injury (SCI) <sup>[1]</sup> .
IC <sub>50</sub> & Target	RAR β <sub>2</sub> <sup>[1]</sup>

## REFERENCES

[1]. Goncalves MB, et al. Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel retinoic acid receptor-β agonist for treatment of spinal cord injury, in male healthy participants. Br J Clin Pharmacol. 2023 Jul 15..

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA